case_images: PMC3750722_01
case_images: Reproductive hormone profile for Participant 1. This figure displays the reproductive hormone profile during the study for Participant 1 and the changes in caloric intake, body weight, and energy status that coincided with each category of menstrual recovery. Arrows indicate menses. Body weight was measured within 1 week of menses.   Indicates data were collected 2 weeks before menses.   Indicates data were collected 6 weeks after menses. %BF: percent body fat; BMI: body mass index; BW: body weight; E1G: estrone-1-glucuronide; PdG: pregnanediol glucuronide; REE/pREE: measured resting energy expenditure/predicted resting energy expenditure; TT3: total triiodothyronine.
case_images: 1550-2783-10-34-1.jpg
case_images: PMC3750722_01_1550-2783-10-34-1.jpg
case_images: F1
case_images: Despite presenting with a normal BMI of 20.4 kg/m2 and body fat of 20.6%, she had been amenorrheic for 11 months when the intervention commenced and urinary analysis of E1G and PdG confirmed suppressed ovarian activity (Table 1, Figure 1). After 2.5 months (74 days) in the intervention, menses resumed (Figure 1). For the first two months after resumption, two consistently eumenorrheic but anovulatory cycles of 28 to 33 days in length were observed (Figure 1).
case_images: PMC3750722_02
case_images: Reproductive hormone profile for Participant 2. This figure displays the reproductive hormone profile during the study for Participant 2 and the changes in caloric intake, body weight, and energy status that coincided with each category of menstrual recovery. Arrows indicate menses.   Indicates data were collected 5 weeks after menses.   Indicates data were collected 3 days after menses. %BF: percent body fat; BMI: body mass index; BW: body weight; E1G: estrone-1-glucuronide; nr: not reported; PdG: pregnanediol glucuronide; REE/pREE: measured resting energy expenditure/predicted resting energy expenditure; TT3: total triiodothyronine.
case_images: 1550-2783-10-34-2.jpg
case_images: PMC3750722_02_1550-2783-10-34-2.jpg
case_images: F2
case_images: The participant resumed menses 23 days after the start of the intervention, an event that was preceded by ovulation (Figure 2). For the remaining 7 months of the study, 8 more cycles were reported, with consistent cycle lengths of 24 to 29 days (Figure 2).